Methods of treating an overweight subject
US-9649293-B2 · May 16, 2017 · US
Methods of treating an overweight subject
US10406134B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10406134-B2 |
| Application number | US-201715484399-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 11, 2017 |
| Priority date | Apr 7, 2010 |
| Publication date | Sep 10, 2019 |
| Grant date | Sep 10, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of decreasing blood glucose and/or blood insulin in a patient in need thereof, wherein the patient is overweight and is not obese, comprising administering to the patient an effective amount of an irreversible fumagillin analog or pharmaceutically acceptable salt thereof that covalently binds to MetAP2, and wherein the effective amount does not substantially suppress angiogenesis. 2. The method of claim 1 , wherein the patient is suffering from type 2 diabetes. 3. The method of claim 1 , wherein the patient has impaired glucose tolerance and/or impaired fasting glucose. 4. The method of claim 1 , wherein the fumagillin analog is administered subcutaneously or intravenously. 5. The method of claim 1 , wherein the fumagillin analog is administered orally. 6. The method of claim 1 , wherein administration occurs at least daily. 7. The method of claim 1 , wherein administration occurs at least weekly.
Assignees
Inventors
Classifications
against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title
the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Stem-loop; Hairpin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10406134B2 cover?
- The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.
- Who is the assignee on this patent?
- Zafgen Inc, Univ Vanderbilt
- What technology area does this patent fall under?
- Primary CPC classification A61K31/336. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).